Small Molecule FLT3 Tyrosine Kinase Inhibitors
Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine
kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.
Keywords: AML; FLT3; kinase inhibitor; tyrosine kinase
Document Type: Research Article
Affiliations: Johns Hopkins University School of Medicine, Departments of 1Oncology and 2Pediatrics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room 251, 1650 Orleans Street, Baltimore, Maryland 21231-1000, USA.
Publication date: 01 January 2006
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content